Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Stayble Therapeutics

0.17 SEK

-3.35 %

Less than 1K followers

STABL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Stayble Therapeutics

2019202020212022202320242025
Revenue
growth-%
EBITDA-6.9-14.9-12.1-24.8-24.0-12.8-
EBIT-6.9-14.9-12.1-24.8-24.0-12.8-6.9
Profit before taxes-7.4-15.5-12.1-24.5-23.7-12.4-6.9
Net income-7.4-15.5-12.1-24.5-23.7-12.4-6.9
EPS-0.83-1.74-0.85-1.72-0.92-0.33-0.12
Dividend0.000.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%
EBIT-%
ROE2,511.2 %-99.6 %-30.4 %-160.5 %-143.8 %-180.8 %-100.1 %
ROI-76.2 %-86.1 %-27.7 %-128.1 %-109.4 %-134.1 %-80.4 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.